Lethal iron deprivation induced by non-neutralizing antibodies targeting transferrin receptor 1 in malignant B cells

Leukemia and Lymphoma

Volumn 52, Issue 11, 2011, Pages 2169-2178

  Rodriguez, José A ^a,b   Luria Pérez, Rosendo ^b,e   López Valdés, Héctor E ^c   Casero, David ^c   Daniels, Tracy R ^b   Patel, Shabnum ^b   Avila, David ^b   Leuchter, Richard ^b   So, Sokuntheavy ^b   Ortiz Snchez, Elizabeth ^b   Bonavida, Benjamin ^c,d   Martnez Maza, Otoniel ^a,c,d   Charles, Andrew C ^c   Pellegrini, Matteo ^c   Helguera, Gustavo ^b   Penichet, Manuel L ^a,b,c,d  

^a Department of Molecular Biology Institute ^*  (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Immunology and Molecular Genetics   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Children's Hospital of Mexico Federico Gomez   (Mexico)

Author keywords

Antibody; Iron deprivation; Transferrin

Indexed keywords

ANTINEOPLASTIC AGENT; CD71 ANTIGEN; MONOCLONAL ANTIBODY CH128.1; MONOCLONAL ANTIBODY CH128.1AV; PROTEIN P53; RECEPTOR ANTIBODY; RECOMBINANT ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY COMBINING SITE; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG RECEPTOR BINDING; DRUG TARGETING; HUMAN; HUMAN CELL; INTERNALIZATION; IRON DEPLETION; LETHAL IRON DEPRIVATION; LYMPHOMA CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSCRIPTION REGULATION;

ANIMALS; ANTIBODIES; ANTIGENS, CD; B-LYMPHOCYTES; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DEFEROXAMINE; ENDOCYTOSIS; GENE EXPRESSION PROFILING; HUMANS; IMMUNOBLOTTING; IRON; MICE; MICE, SCID; MULTIPLE MYELOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN BINDING; RECEPTORS, TRANSFERRIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIDEROPHORES; TRANSFERRIN; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80054999211     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.596964     Document Type: Article

References (37)

1. Ponka P, Lok CN. The transferrin receptor: role in health and disease. Int J Biochem Cell Biol 1999;31:1111-1137.
2. Daniels TR, Delgado T, Rodriguez JA, et al. The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol 2006;121:144-158.
3. Ciechanover A, Schwartz AL, Lodish HF. Sorting and recycling of cell surface receptors and endocytosed ligands: the asialo glycoprotein and transferrin receptors. J Cell Biochem 1983;23:107-130.
4. Larrick JW, Enns C, Raubitschek A, et al. Receptor-mediated endocytosis of human transferrin and its cell surface receptor. J Cell Physiol 1985;124:283-287.
5. Das Gupta A, Shah VI. Correlation of transferrin receptor expression with histologic grade and immunophenotype in chronic lymphocytic leukemia and non-Hodgkin 's lymphoma. Hematol Pathol 1990;4:37-41.
6. White S, Taetle R, Seligman PA, et al. Combinations of antitransferrin receptor monoclonal antibodies inhibit human tumor cell growth in vitro and in vivo: evidence for synergistic antiproliferative effects. Cancer Res 1990;50:6295-6301.
7. Kasibhatla S, Jessen KA, Maliartchouk S, et al. A role for transferrin receptor in triggering apoptosis when targeted with gambogic acid. Proc Natl Acad Sci USA 2005;102:12095-12100.
8. Horonchik L, Wessling-Resnick M. The small-molecule iron transport inhibitor ferristatin/NSC306711 promotes degradation of the transferrin receptor. Chem Biol 2008;15:647-653.
9. Ng PP, Dela Cruz JS, Sorour DN, et al. An anti-transferrin receptoravidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells. Proc Natl Acad Sci USA 2002;99:10706-10711.
10. Callens C, Moura IC, Lepelletier Y, et al. Recent advances in adult T-cell leukemia therapy: focus on a new anti-transferrin receptor monoclonal antibody. Leukemia 2008;22:42-48.
11. Daniels TR, Delgado T, Helguera G, et al. The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin Immunol 2006;121:159-176.
12. Crepin R, Goenaga AL, Jullienne B, et al. Development of human single-chain antibodies to the transferrin receptor that effectively antagonize the growth of leukemias and lymphomas. Cancer Res 2010;70:5497-5506.
13. Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007;2:751-760.
14. Ng PP, Helguera G, Daniels TR, et al. Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor. Blood 2006;108:2745-2754.
15. Laubach JP, Richardson PG, Anderson KC. The evolution and impact of therapy in multiple myeloma. Med Oncol 2010;27(Suppl. 1):S1-S6.
16. Daniels TR, Ng PP, Delgado T, et al. Conjugation of an anti transferrin receptor IgG3-avidin fusion protein with biotinylated saporin results in significant enhancement of its cytotoxicity against malignant hematopoietic cells. Mol Cancer Th er 2007;6:2995-3008.
17. Rodriguez JA, Helguera G, Daniels TR, et al. Binding specificity and internalization properties of an antibody-avidin fusion protein targeting the human transferrin receptor. J Control Release 2007;124:35-42.
18. Ortiz-Sanchez E, Daniels TR, Helguera G, et al. Enhanced cytotoxicity of an anti-transferrin receptor IgG3-avidin fusion protein in combination with gambogic acid against human malignant hematopoietic cells: functional relevance of iron, the receptor, and reactive oxygen species. Leukemia 2009;23:59-70.
19. Xia F, Wang X, Wang YH, et al. Altered p53 status correlates with differences in sensitivity to radiation-induced mutation and apoptosis in two closely related human lymphoblast lines. Cancer Res 1995;55:12-15.
20. Lu TP, Lai LC, Lin BI, et al. Distinct signaling pathways after higher or lower doses of radiation in three closely related human lymphoblast cell lines. Int J Radiat Oncol Biol Phys 2010;76:212-219.
21. Simunek T, Boer C, Bouwman RA, et al. SIH-a novel lipophilic iron chelator-protects H9c2 cardiomyoblasts from oxidative stress-induced mitochondrial injury and cell death. J Mol Cell Cardiol 2005;39:345-354.
22. Beltran-Parrazal L, Lopez-Valdes HE, Brennan KC, et al. Mitochondrial transport in processes of cortical neurons is independent of intracellular calcium. Am J Physiol Cell Physiol 2006;291:C1193-1197.
23. Kirchhausen T, Macia E, Pelish HE. Use of dynasore, the small molecule inhibitor of dynamin, in the regulation of endocytosis. Methods Enzymol 2008;438:77-93.
24. Feo-Zuppardi FJ, Taylor CW, Iwato K, et al. Long-term engraftment of fresh human myeloma cells in SCID mice. Blood 1992;80:2843-2850.
25. Markman M. Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol 2003;4:277-283.
26. Breuer W, Epsztejn S, Cabantchik ZI. Dynamics of the cytosolic chelatable iron pool of K562 cells. FEBS Lett 1996;382:304-308.
27. Lin SM, Du P, Huber W, et al. Model-based variance-stabilizing transformation for Illumina microarray data. Nucleic Acids Res 2008;36:e11.
28. Daniels TR, Neacato II, Rodriguez JA, et al. Disruption of HOX activity leads to cell death that can be enhanced by the interference of iron uptake in malignant B cells. Leukemia 2010;24:1555-1565.
29. Saletta F, Rahmanto YS, Noulsri E, et al. Iron chelator-mediated alterations in gene expression: identification of novel iron-regulated molecules that are molecular targets of hypoxia-inducible factor-1 alpha and p53. Mol Pharmacol 2010;77:443-458.
30. Richardson DR, Kalinowski DS, Lau S, et al. Cancer cell iron metabolism and the development of potent iron chelators as antitumour agents. Biochim Biophys Acta 2009;1790:702-717.
31. Gao J, Richardson DR. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: the mechanisms involved in inhibiting cell-cycle progression. Blood 2001;98:842-850.
32. Suzuki E, Daniels TR, Helguera G, et al. Inhibition of NF-kappaB and Akt pathways by an antibody-avidin fusion protein sensitizes malignant B-cells to cisplatin-induced apoptosis. Int J Oncol 2010;36:1299-1307.
33. Taetle R, Castagnola J, Mendelsohn J. Mechanisms of growth inhibition by anti-transferrin receptor monoclonal antibodies. Cancer Res 1986;46:1759-1763.
34. Moura IC, Lepelletier Y, Arnulf B, et al. A neutralizing monoclonal antibody (mAb A24) directed against the transferrin receptor induces apoptosis of tumor T lymphocytes from ATL patients. Blood 2004;103:1838-1845.
35. Tacchini L, Bianchi L, Bernelli-Zazzera A, et al. Transferrin receptor induction by hypoxia. HIF-1-mediated transcriptional activation and cell-specific post-transcriptional regulation. J Biol Chem 1999;274:24142-24146.
36. Piccinelli P, Samuelsson T. Evolution of the iron-responsive element. RNA 2007;13:952-966.
37. Templeton DM, Liu Y. Genetic regulation of cell function in response to iron overload or chelation. Biochim Biophys Acta 2003;1619:113-124.